Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 5/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.36 |
| ▸ | STAT3 | P40763 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14719379 | 0.91 | L3MBTL1 (0.39) | MAPTL3MBTL1MAPK1TDP1BRD4 | |
| SCHEMBL14719133 | 0.90 | PTGER1 (0.38) | MAPTL3MBTL1MAPK1TDP1BRD4 | |
| SCHEMBL14719169 | 0.86 | MAPT (0.40) | MAPTL3MBTL1MAPK1TDP1BRD4 | |
| SCHEMBL14718568 | 0.84 | MRGPRX4 (0.37) | MAPTL3MBTL1MAPK1TDP1BRD4 | |
| SCHEMBL14719454 | 0.83 | L3MBTL1 (0.41) | MAPTL3MBTL1MAPK1TDP1BRD4 | |
| SCHEMBL14719167 | 0.83 | GRM5 (0.41) | MAPTL3MBTL1MAPK1TDP1LMNA | |
| SCHEMBL14718952 | 0.83 | ABCB1 (0.45) | MAPTL3MBTL1MRGPRX4HTTSMN1; SMN2 | |
| SCHEMBL14718770 | 0.82 | PTGER1 (0.38) | MAPTL3MBTL1MAPK1TDP1BRD4 | |
| SCHEMBL14718411 | 0.80 | NPC1 (0.40) | MAPTL3MBTL1MAPK1TDP1BRD4 | |
| SCHEMBL14718866 | 0.80 | MRGPRX4 (0.42) | MAPTL3MBTL1MAPK1TDP1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-07 | — | — | US | disclosed |
| US-20220008416-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| US-20220008416-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| US-11129828-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-28 | — | — | US | disclosed |
| US-11129828-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-28 | — | — | US | disclosed |
| US-20200121678-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-04-23 | — | — | US | disclosed |
| US-10463663-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-11-05 | — | — | US | disclosed |
| US-10463663-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-11-05 | — | — | US | disclosed |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-28 | — | — | US | disclosed |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-28 | — | — | US | disclosed |
| US-9290456-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-22 | — | — | US | disclosed |
| EP-2748149-B1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-10-21 | — | — | EP | disclosed |
| EP-2748149-B1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| EP-2748149-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2014-07-02 | — | — | EP | disclosed |
| WO-2013027000-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052281-A1 | NOVEL COMPOUNDS | ABCG2, F12, UGT1A1 | MAPT 2770/4885L3MBTL1 4060/4885MAPK1 3374/4885 |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | MAPT 2902/4885L3MBTL1 4285/4885MAPK1 1645/4885 |
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | MAPT 2902/4885L3MBTL1 4285/4885MAPK1 1645/4885 |
| US-20200121678-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | MAPT 2902/4885L3MBTL1 4285/4885MAPK1 1645/4885 |
| US-11129828-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | MAPT 2902/4885L3MBTL1 4285/4885MAPK1 1645/4885 |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | MAPT 2902/4885L3MBTL1 4285/4885MAPK1 1645/4885 |
| US-10463663-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | MAPT 2902/4885L3MBTL1 4285/4885MAPK1 1645/4885 |
| US-20220008416-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | MAPT 2902/4885L3MBTL1 4285/4885MAPK1 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.